Use the hyperlinks, where available to access additional clinical trial information.
Single arm, open label, signal seeking, phase II trial of the activity of Palbociclib in combination with Avelumab in patients with tumours with amplified D-type cyclins or CDK4/6 or inactivation of CDKN2A.
Australian Genomic Cancer Medicine Centre (AGCMC)
Other Non-Commercial Sponsor
University of Sydney
This is an open-label trial for patients with solid cancers with amplified D-type cyclins or CDK4/5 or inactivation of CDKN2A. All participants will receive Palbociclib first on its own in the first cycle of treatment. Palbociclib will be administered orally at a dose of 125mg once daily for 21 days, followed by 7 days of washout. This dosage may be reduced if participants experiences intolerance toxicity. Avelumab will be administered intravenously at a dose of 10mg/kg every 2 weeks, starting from the second cycle of treatment. Both drugs will be administered continuously until disease progression is documented or when the participant experiences intolerable toxicity or withdraws for another reason.